Structure Therapeutics (GPCR) Capital Expenditures (2022 - 2026)

Structure Therapeutics' Capital Expenditures history runs 5 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 276.43% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.8 million (up 22.19% YoY), while the FY2025 annual figure was $894000.0, down 30.7% from the prior year.
• Capital Expenditures was $1.2 million for Q1 2026 at Structure Therapeutics, up from -$1.2 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.9 million in Q4 2023 to a low of -$1.2 million in Q4 2025.
• Historically, Capital Expenditures has averaged $366466.7 across 5 years, with a median of $162000.0 in 2024.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures surged 2512.68% in 2023, then tumbled 7750.0% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $71000.0 in 2022, then soared by 2512.68% to $1.9 million in 2023, then sank by 99.14% to $16000.0 in 2024, then sank by 7750.0% to -$1.2 million in 2025, then soared by 196.57% to $1.2 million in 2026.
• The last three Capital Expenditures figures came in at $1.2 million (Q1 2026), -$1.2 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.